Clinical Trial

Fingolimod for Type 2 Diabetes Mellitus

Recruiting Phase 4

Record status

This record was last updated August 21, 2025 (before its estimated March 15, 2026 completion). Its status may not reflect the trial's current state.

Summary

The aim of this study is to explore the efficacy and safety of Fingoland in the treatment of type 2 diabetes. A total of 40 patients were randomly divided into two groups. One group was treated with fingolimod, another group was given guideline based treatment. The changes of islet function in patients with glycosylated hemoglobin, insulin and C-peptide were observed .

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2022-03-31; most recent amendment 2025-08-20.

Trial Details

NCT Number	NCT05307731
Lead Sponsor	General Hospital of Shenyang Military Region
Conditions	Diabetes Mellitus, Type 2
Enrollment	40 participants
Start Date	2022-03-15
Primary Completion	2026-03-15 (estimated)
Study Completion	2026-03-15 (estimated)
Updated on ClinicalTrials.gov	2025-08-21